Health In Tech announced an expansion of its stop-loss self-funded healthcare plan offerings. In connection with this expansion, Health In Tech also announced a strategic collaboration with Benefit Re. "We are excited to launch more than 100 customized stop-loss healthcare plans in collaboration with Benefit Re," said Tim Johnson, CEO of Health In Tech. "These programs expand meaningful choice for employers while providing proven tools to manage rising healthcare costs. Our AI-backed platform enables rapid execution of Benefit Re's underwriting criteria and accelerates deployment of cost-containment, faster claims processing programs. Partnering with retention-driven carriers with strong performance records is critical in today's cost-pressured healthcare environment. Importantly, this collaboration also creates future opportunities to expand into property & casualty offerings for our business customers."
Wall Street analysts forecast HIT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIT is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HIT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HIT is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.480
Low
4.50
Averages
4.50
High
4.50
Current: 1.480
Low
4.50
Averages
4.50
High
4.50
Maxim
NULL -> Buy
initiated
$2.50
2025-06-26
Reason
Maxim
Price Target
$2.50
AI Analysis
2025-06-26
initiated
NULL -> Buy
Reason
Maxim initiated coverage of Health In Tech with a Buy rating and $2.50 price target.
Maxim
Buy
initiated
$2.50
2025-06-26
Reason
Maxim
Price Target
$2.50
2025-06-26
initiated
Buy
Reason
Maxim initiated coverage of Health In Tech with a Buy rating and $2.50 price target. The company operates in a multi-billion-dollar market, with mostly recurring revenue and high gross margin, and the firm expects growth from new services and expansion into the mid-size employer market, the analyst tells investors in a research note. Maxim adds that its rating reflects its positive view of the large market opportunity, competitive advantages, and multiple growth initiatives.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HIT
Unlock Now
About HIT
Health In Tech, Inc. is an Insurtech platform company backed by third-party artificial intelligence technology, which offers a marketplace that aims to improve processes in the healthcare industry through vertical integration, process simplification, and automation. It offers a marketplace designed to create healthcare plan solutions while streamlining processes through vertical integration, process simplification, and automation. Its services are delivered through three subsidiaries: Stone Mountain Risk, LLC (SMR), International Captive Exchange, LLC (ICE), and HI Card LLC’s HI Card platform (HI Card). The SMR is a program manager specializing in customized self-funded programs for small businesses. ICE is a managing general underwriter. ICE assists with underwriting activities through its Web-based SaaS quoting platform, Enhance Do It Yourself Benefit System (eDIYBS). HI Card seeks to simplify healthcare management with a single standardized transaction and service platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
